• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

restasis

  1. Restasis Contract Sales Force

    What does everyone thing about the new contract sales force selling Restasis? I thought they were supposed to be calling on lower volume OD's that were writing Xiidra and instead they have complete overlap with the red and blue reps. Why in the world would Allergan do this? The drug has been...
  2. Brent Saunders says Allergan stock is undervalued

    Allergan swings to quarterly loss on charges related to Restasis and Teva holding. Given the Federal Court's decision, plans to mitigate the financial impact of generic competition http://alph.st/b68181eb